Researchers are testing the effectiveness of Metformin to help improve daily living for individuals with Fragile X syndrome.

The trial further assesses Metformin’s safety, as well as the benefits of the drug, which has been shown to improve the symptoms and difficulties individuals with FXS experience, including: delayed language/cognition, excessive eating, obesity, hypogonadism, and delayed puberty.


Who can participate?

Individuals aged 6–25 who have been diagnosed with FXS (and who fit the inclusion/exclusion criteria).

What will happen in the study?

Commit to a four-month study which includes three clinic visits, and five phone calls while taking Metformin orally. Complete various tasks, questionnaires, and examinations by a physician/research team, as well as have blood drawn, as well as urine and stool samples taken.

Will you/your child be paid to complete this survey?

Travel expenses will be reimbursed.

Study doctors and locations

Please fill out the form below to send your contact information to the study coordinators.

Dr. Francois Bolduc, Principal Investigator
University of Alberta/Stollery Children’s Hospital
Edmonton, Alberta, Canada

Clinical Research Coordinator: Call (780) 492-9461 or email

Dr. Sébastien Jacquemont, Principal Investigator
CHU Ste. Justine
Montreal, Quebec, Canada

Study Coordinators: Maryse Thibeault or Sophie Morin

Our Most Recent Opportunities
If you arrived on this page through a MyFXResearch Portal search, you can close this window and return to your filtered results. Or start a new search here.

PIXI Study: Parent-Infant Fragile X Intervention

RTI International and the University of North Carolina at Chapel Hill are conducting an early intervention study to learn about the best ways to support early development in infants identified with the full mutation of Fragile X. Babies 0–9 months old with the full mutation, and their caregivers, may be eligible to participate.

Study: Our Fragile X World Registry

Our Fragile X World collects data from families using online surveys and in-person studies. Topics covered include sensory or behavioral challenges, health care experiences, and the impact of Fragile X on families.

Fragile X Premutation Carrier Study at USC

The University of South Carolina is conducting a research study focusing on the range of language, social, and cognitive features that may be associated with variations on the FMR1 gene. Women age 35-75 who are carriers of the Fragile X premutation may be eligible to participate.